#Canada #Montreal #Zemcelpro #ExCellThera #dorocubicel

ExCellThera’s Groundbreaking Advancement in Blood Cancer Treatment

ExCellThera Inc., a leader in blood stem cell innovation, is on the verge of reshaping the landscape of high-risk blood cancer treatment. This March, at the 52nd European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Madrid, Spain, the company will present groundbreaking results from their latest trials involving Zemcelpro® (dorocubicel), also known as UM171. This therapy showcases remarkable potential for patients with severe forms of acute leukemias and myelodysplastic syndromes (MDS).

Unveiling the Clinical Trials

The Phase 2 studies encompassed a cohort of 60 adult patients diagnosed with high- and very high-risk acute leukemias or MDS, notoriously known for having dismal survival rates. The findings from these studies will be unveiled on March 23, 2026, providing new hope for patients who have encountered limited options in their battle against this aggressive disease. Previous treatments, often linked to conventional allogeneic stem cell transplantation, yielded poor outcomes with survival rates between 25% and 40%.

At the two-year mark post-transplantation, patients who received Zemcelpro® exhibited an overall survival rate of 63.7%, a progression-free survival rate of 57.0%, and a relapse-free survival rate standing at 60%. These statistics highlight the significant achievement for patients who previously faced a bleak prognosis. Moreover, the incidences of relapse and mortality not related to the disease were recorded at 22.5% and 20.5%, respectively. Notably, younger patients, aged less than 43, showcased superior outcomes with zero non-relapse mortality and survival and progression-free survival rates of 82.8% and 79.3%.

A New Dawn for Blood Cancer Treatment

These positive outcomes are a beacon of hope, suggesting that Zemcelpro® can redefine standard treatment protocols for high-risk blood cancers. According to Dr. Guy Sauvageau, Chief Scientific Officer, this therapy signifies a remarkable leap from existing practices. The lower rates of graft-versus-host disease (GVHD)—20% for grade III-IV and only 7% for moderate to severe chronic GVHD—adds to the favorable profile of this treatment option.

David Millette, CEO of ExCellThera, echoes this optimism, stating that the findings place Zemcelpro® on the forefront of transforming treatment approaches for difficult-to-treat high-risk patients. He emphasizes that this innovative therapy challenges the existing paradigms, promoting a vision where high-risk blood cancer patients can expect better clinical outcomes than previously thought possible.

An Insight into Zemcelpro® (dorocubicel)

Zemcelpro® represents a cutting-edge advancement in hematopoietic stem cell transplantation. This cryopreserved product contains both UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells from the same cord blood unit—providing a personalized treatment avenue for patients with blood malignancies who have deemed standard therapies ineffective. Recent conditional marketing authorization from the European Commission further solidifies its promising status.

The company is preparing for additional regulatory submissions for Zemcelpro® in the United States, Canada, the UK, and Switzerland, signaling their ambition to bring this treatment to market across various international landscapes. Dr. Sauvageau also highlighted the expansive research efforts into Zemcelpro’s efficacy among pediatric populations and patients with non malignant hematological disorders.

Final Thoughts

This year’s EBMT Annual Meeting not only serves as a platform for showcasing these exciting results but also symbolizes the strides being made in the domain of blood cancer treatment. As ExCellThera continues its journey toward commercialization and expanded clinical application of Zemcelpro®, the medical community and patients alike remain hopeful for a brighter future against the grim backdrop of high- and very high-risk blood cancers.

Among the challenges posed by such conditions, the emergence of innovative treatments like Zemcelpro® offers renewed optimism, paving the way for enhanced care standards and improved lives.